Literature DB >> 21507087

Effect of dexamethasone and testosterone treatment on the regulation of insulin-degrading enzyme and cellular changes in ventral rat prostate after castration.

Juliany S B César Vieira1, Karina L A Saraiva, Maria C L Barbosa, Regina C C Porto, Juan C Cresto, Christina A Peixoto, Maria I Wanderley, Daniel P Udrisar.   

Abstract

Insulin-degrading enzyme (IDE) has been shown to enhance the binding of androgen and glucocorticoid receptors to DNA in the nuclear compartment. Glucocorticoids cause hyperglycaemia, peripheral resistance to insulin and compensatory hyperinsulinaemia. The aim of the present study was to investigate the effect of dexamethasone (D), testosterone (T) and dexamethasone plus testosterone (D + T) on the regulation of IDE and on the remodelling of rat ventral prostate after castration (C). Castration led to a marked reduction in prostate weight (PW). Body weight was significantly decreased in the castrated animals treated with dexamethasone, and the relative PW was 2.6-fold (±0.2) higher in the D group, 2.8-fold (±0.3) higher in the T group and 6.6-fold (±0.6) higher in the D + T group in comparison with the castrated rats. Ultrastructural alterations in the ventral prostate in response to androgen deprivation were restored after testosterone and dexamethasone plus testosterone treatments and partially restored with dexamethasone alone. The nuclear IDE protein level indicated a 4.3-fold (±0.4) increase in castrated rats treated with D + T when compared with castration alone. Whole-cell IDE protein levels increased approximately 1.5-fold (±0.1), 1.5-fold (±0.1) and 2.9-fold (±0.2) in the D, T and D + T groups, respectively, when compared with castration alone. In conclusion, the present study reports that dexamethasone-induced hyperinsulinaemic condition plus exogenous testosterone treatment leads to synergistic effects of insulin and testosterone in the prostatic growth and in the amount of IDE in the nucleus and whole epithelial cell.
© 2011 The Authors. International Journal of Experimental Pathology © 2011 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507087      PMCID: PMC3144516          DOI: 10.1111/j.1365-2613.2011.00772.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  49 in total

Review 1.  Regulation of prostatic growth and function by peptide growth factors.

Authors:  Z Culig; A Hobisch; M V Cronauer; C Radmayr; A Hittmair; J Zhang; M Thurnher; G Bartsch; H Klocker
Journal:  Prostate       Date:  1996-06       Impact factor: 4.104

Review 2.  Growth factors as mediators of androgen action during male urogenital development.

Authors:  G R Cunha
Journal:  Prostate Suppl       Date:  1996

3.  Preprostatectomy: A clinical model to study stromal-epithelial interactions.

Authors:  W Lopaczynski; A M Hruszkewycz; R Lieberman
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

4.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

5.  E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth.

Authors:  Sathish Srinivasan; Zafar Nawaz
Journal:  Biochim Biophys Acta       Date:  2010-09-06

6.  Androgen- and estrogen-dependent regulation of insulin-degrading enzyme in subcellular fractions of rat prostate and uterus.

Authors:  Daniel P Udrisar; Maria I Wanderley; Regina C C Porto; Carla L P Cardoso; Maria C L Barbosa; Maria C Camberos; Juan C Cresto
Journal:  Exp Biol Med (Maywood)       Date:  2005-07

7.  Insulin processing. Its correlation with glucose conversion to CO2.

Authors:  D P Udrisar; M C Camberos; J C Basabe; J C Cresto
Journal:  Acta Physiol Pharmacol Latinoam       Date:  1984

8.  Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion.

Authors:  Karina Lidianne Alcântara Saraiva; Amanda Karolina Soares E Silva; Maria Inês Wanderley; Araken Almeida De Araújo; José Roberto Botelho De Souza; Christina Alves Peixoto
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

9.  Fluoride and phosphatidylserine induced inhibition of cytosolic insulin-degrading activity.

Authors:  D P Udrisar; M I Wanderley
Journal:  Acta Physiol Pharmacol Ther Latinoam       Date:  1992

10.  Cellular changes in the prostatic stroma of glucocorticoid-treated rats.

Authors:  D L Ribeiro; A Rafacho; J R Bosqueiro; S R Taboga; R M Góes
Journal:  Cell Tissue Res       Date:  2008-04-01       Impact factor: 5.249

View more
  4 in total

1.  II - Insulin processing in mitochondria.

Authors:  María Del Carmen Camberos; Adriana A Pérez; Gisel A Passicot; Lucía C Martucci; María I Wanderley; Daniel P Udrisar; Juan C Cresto
Journal:  J Bioenerg Biomembr       Date:  2016-10-29       Impact factor: 2.945

2.  I - insulin transfer to mitochondria.

Authors:  María Del Carmen Camberos; Gabriel Cao; María I Wanderley; Daniel P Udrisar; Juan C Cresto
Journal:  J Bioenerg Biomembr       Date:  2014-08-08       Impact factor: 2.945

3.  Reduction of insulin signalling pathway IRS-1/IRS-2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid-treated rats.

Authors:  Maitê M Costa; Natália M Violato; Sebastião R Taboga; Rejane M Góes; José R Bosqueiro
Journal:  Int J Exp Pathol       Date:  2012-06       Impact factor: 1.925

Review 4.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.